Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2009.24.1455PMID 19917861PMCID PMC2799230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

  2009cited by this paper
• Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

  2009cited by this paper
• Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

  2008cited by this paper
• Epothilones and new analogues of the microtubule modulators in taxane-resistant disease.

  2008cited by this paper
• New tubulin targeting agents currently in clinical development

  2008cited by this paper
• The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

  2008cited by this paper
• Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.

  2008cited by this paper
• Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

  2007cited by this paper
• Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

  2007cited by this paper
• Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes

  2007cited by this paper
• Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

  2007cited by this paper
• Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

  2007cited by this paper
• Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.

  2007cited by this paper
• Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.

  2007cited by this paper
• Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.

  2006cited by this paper
• Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

  2006cited by this paper
• Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients

  2006cited by this paper
• Chromosomal Instability, Colorectal Cancer and Taxane Resistance

  2006cited by this paper
• Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.

  2006cited by this paper
• Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

  2005cited by this paper
• Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer

  2005cited by this paper
• Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers

  2004cited by this paper
• Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers.

  2004cited by this paper
• Dependence of Paclitaxel Sensitivity on a Functional Spindle Assembly Checkpoint

  2004cited by this paper
• Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.

  2004cited by this paper
• Epothilones: mechanism of action and biologic activity.

  2004cited by this paper
• Do beta-tubulin mutations have a role in resistance to chemotherapy?

  2004cited by this paper
• Class III B-Tubulin Overexpression Is a Prominent Mechanism of Paclitaxel Resistance in Ovarian Cancer Patients

  2004cited by this paper
• Do β-tubulin mutations have a role in resistance to chemotherapy?

  2004cited by this paper
• Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors

  2004cited by this paper
• A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

  2001cited by this paper
• Novel molecules that interact with microtubules and have functional activity similar to Taxol.

  2001cited by this paper
• Optimal flexible designs in phase II clinical trials.

  1998cited by this paper
• Activities of the Microtubule-stabilizing Agents Epothilones A and B with Purified Tubulin and in Cells Resistant to Paclitaxel (Taxol®)*

  1997cited by this paper

• Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses

  2024cites this paper
• A Recipe for Successful Metastasis: Transition and Migratory Modes of Ovarian Cancer Cells

  2024cites this paper
• Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy.

  2024cites this paper
• Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study

  2023cites this paper
• Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

  2022influential citation
• Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial

  2022cites this paper
• Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies

  2021cites this paper
• Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens

  2021cites this paper
• Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment

  2021influential citation
• Patient Benefit and Risk in Anticancer Drug Development: A Systematic Review of the Ixabepilone Trial Portfolio

  2019cites this paper
• Extensive Intratumor Proteogenomic Heterogeneity Revealed by Multiregion Sampling in a High-Grade Serous Ovarian Tumor Specimen

  2019cites this paper
• Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies

  2017cites this paper
• Targeting PAM signaling pathway in the treatment of pancreatic ductal adenocarcinoma

  2017cites this paper
• Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer

  2017cites this paper
• An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma

  2017cites this paper
• New potential chemotherapy for ovarian cancer - Combined therapy with WP 631 and epothilone B.

  2016cites this paper
• Improving the drug development process by reducing the impact of adverse events: the case of cataracts considered.

  2016cites this paper
• Recurrent Ovarian Cancer — Basic Knowledge, Current Management, and Future Directions

  2016cites this paper
• Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

  2015cites this paper
• Early metabolic change in 18F-FDG-PET by measuring the single largest lesion predicts chemotherapeutic effects and patients’ survival: PEACH study

  2015cites this paper
• Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

  2015cites this paper
• Referrals to phase I clinical trials in a gynecologic oncology unit.

  2014cites this paper
• Development of other microtubule-stabilizer families: the epothilones and their derivatives

  2014cites this paper
• From bacteria to antineoplastic: epothilones a successful history.

  2013cites this paper
• Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010.

  2013cites this paper
• Novel facts about FAK: new connections to drug resistance?

  2013cites this paper
• Current status of bevacizumab in advanced ovarian cancer

  2013cites this paper
• Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.

  2013cites this paper
• Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer

  2013cites this paper
• Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?

  2013cites this paper
• Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

  2013cites this paper
• Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.

  2012cites this paper
• Antimitotic inhibitors.

  2012cites this paper
• A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

  2012cites this paper
• A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy

  2012cites this paper
• Phase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic Malignancies

  2012cites this paper
• RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.

  2012cites this paper
• Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.

  2012cites this paper
• Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors

  2012cites this paper
• Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.

  2012cites this paper
• Novel drugs targeting microtubules: the role of epothilones.

  2012cites this paper
• Targeted therapy for high-risk endometrial carcinoma

  2012cites this paper
• Chemotherapy-Induced Neuropathic Pain

  2012cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Review of Clinical Studies

  2012cites this paper
• Emerging chemotherapy agents in ovarian cancer

  2012cites this paper
• Chemotherapeutic management of recurrent ovarian cancer

  2012cites this paper
• Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer

  2011cites this paper
• Cell Death Signaling and Anticancer Therapy

  2011cites this paper
• New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer

  2011cites this paper
• Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients

  2011cites this paper
• New Insights into Tubulin Binders

  2011cites this paper
• Epothilones in the treatment of ovarian cancer.

  2011cites this paper
• The pharmacogenomics of vincristine-induced neurotoxicity in paediatric cancer patients with Wilms tumor or rhabdomyosarcoma

  2011cites this paper
• Recurrent Ovarian Cancer: When and How to Treat

  2011cites this paper
• Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence

  2011cites this paper
• Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.

  2011cites this paper
• Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells.

  2011cites this paper
• Targeted treatment of recurrent platinum-resistant ovarian cancer : current and emerging therapies

  2010cites this paper
• The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.

  2010cites this paper
• Microtubule-binding agents: a dynamic field of cancer therapeutics

  2010cites this paper
• Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.

  2010cites this paper
• Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents

  2010cites this paper
• Optimal treatment for relapsing ovarian cancer.

  2010cites this paper
• Chemotherapy and signaling

  2010cites this paper
• Overcoming platinum resistance in ovarian carcinoma

  2010cites this paper
• Oncotargets and Therapy Dovepress Dovepress Epothilones in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: a Systematic Review

  year unknowncites this paper